MDRX Quote, Financials, Valuation and Earnings

LENZ Therapeutics has a net margin of -- compared to Veradigm's net margin of --. Veradigm's return on equity of -- beat LENZ Therapeutics's return on equity of --.

Veradigm has a consensus price target of $10.00, signalling upside risk potential of 135.29%. On the other hand LENZ Therapeutics has an analysts' consensus of $42.63 which suggests that it could grow by 63.88%. Given that Veradigm has higher upside potential than LENZ Therapeutics, analysts believe Veradigm is more attractive than LENZ Therapeutics.

Veradigm has a beta of 0.627, which suggesting that the stock is 37.279% less volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Veradigm has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. Veradigm pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.

Veradigm quarterly revenues are --, which are smaller than LENZ Therapeutics quarterly revenues of --. Veradigm's net income of -- is lower than LENZ Therapeutics's net income of -$12.7M. Notably, Veradigm's price-to-earnings ratio is -- while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm is 0.89x versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

LifeMD has a net margin of -- compared to Veradigm's net margin of -0.17%. Veradigm's return on equity of -- beat LifeMD's return on equity of --.

Veradigm has a consensus price target of $10.00, signalling upside risk potential of 135.29%. On the other hand LifeMD has an analysts' consensus of $11.94 which suggests that it could grow by 122.02%. Given that Veradigm has higher upside potential than LifeMD, analysts believe Veradigm is more attractive than LifeMD.

Veradigm has a beta of 0.627, which suggesting that the stock is 37.279% less volatile than S&P 500. In comparison LifeMD has a beta of 2.221, suggesting its more volatile than the S&P 500 by 122.141%.

Veradigm has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeMD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veradigm pays -- of its earnings as a dividend. LifeMD pays out -16.45% of its earnings as a dividend.

Veradigm quarterly revenues are --, which are smaller than LifeMD quarterly revenues of $64.3M. Veradigm's net income of -- is lower than LifeMD's net income of -$106.3K. Notably, Veradigm's price-to-earnings ratio is -- while LifeMD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm is 0.89x versus 1.05x for LifeMD. Usually stocks with elevated PS ratios are considered overvalued.

Streamline Health Solutions has a net margin of -- compared to Veradigm's net margin of -56.03%. Veradigm's return on equity of -- beat Streamline Health Solutions's return on equity of -54.79%.

Veradigm has a consensus price target of $10.00, signalling upside risk potential of 135.29%. On the other hand Streamline Health Solutions has an analysts' consensus of $22.50 which suggests that it could fall by -44.84%. Given that Veradigm has higher upside potential than Streamline Health Solutions, analysts believe Veradigm is more attractive than Streamline Health Solutions.

Veradigm has a beta of 0.627, which suggesting that the stock is 37.279% less volatile than S&P 500. In comparison Streamline Health Solutions has a beta of 1.743, suggesting its more volatile than the S&P 500 by 74.296%.

Veradigm has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Streamline Health Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veradigm pays -- of its earnings as a dividend. Streamline Health Solutions pays out -- of its earnings as a dividend.

Veradigm quarterly revenues are --, which are smaller than Streamline Health Solutions quarterly revenues of $4.4M. Veradigm's net income of -- is lower than Streamline Health Solutions's net income of -$2.5M. Notably, Veradigm's price-to-earnings ratio is -- while Streamline Health Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm is 0.89x versus 0.58x for Streamline Health Solutions. Usually stocks with elevated PS ratios are considered overvalued.

TruBridge has a net margin of -- compared to Veradigm's net margin of -3.37%. Veradigm's return on equity of -- beat TruBridge's return on equity of -11.47%.

Veradigm has a consensus price target of $10.00, signalling upside risk potential of 135.29%. On the other hand TruBridge has an analysts' consensus of $29.25 which suggests that it could grow by 7.62%. Given that Veradigm has higher upside potential than TruBridge, analysts believe Veradigm is more attractive than TruBridge.

Veradigm has a beta of 0.627, which suggesting that the stock is 37.279% less volatile than S&P 500. In comparison TruBridge has a beta of 0.640, suggesting its less volatile than the S&P 500 by 36.048%.

Veradigm has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TruBridge offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veradigm pays -- of its earnings as a dividend. TruBridge pays out -- of its earnings as a dividend.

Veradigm quarterly revenues are --, which are smaller than TruBridge quarterly revenues of $90.8M. Veradigm's net income of -- is lower than TruBridge's net income of -$3.1M. Notably, Veradigm's price-to-earnings ratio is -- while TruBridge's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm is 0.89x versus 1.13x for TruBridge. Usually stocks with elevated PS ratios are considered overvalued.